patient
respiratori
infect
often
manag
presumpt
confirm
infect
statu
assess
impact
introduc
fluabrsv
pointofcar
test
poct
patient
admit
suspect
respiratori
viru
driven
ill
acut
pediatr
ward
util
design
respiratori
viral
season
versu
follow
poct
implement
oseltamivir
prescrib
increas
patient
influenza
p
ci
reduct
averag
reimburs
charg
without
chang
length
stay
observ
model
suggest
laboratori
test
cost
save
could
achiev
poct
cost
use
screen
follow
respiratori
viral
panel
rsv
influenza
neg
patient
rapid
poct
influenza
ab
rsv
infect
pediatr
inpati
may
improv
oseltamivir
prescrib
strengthen
antimicrobi
stewardship
reduc
reimburs
charg
decreas
laboratori
cost
influenza
respiratori
syncyti
virus
rsv
common
caus
respiratori
infect
particularli
sever
children
result
signific
mortal
nair
et
al
unit
kingdom
uk
children
age
year
compris
influenzaattribut
hospit
admiss
cromer
et
al
estim
hospit
admiss
rate
influenza
previous
healthi
children
age
five
year
reach
per
annual
england
five
time
greater
children
age
comorbid
cromer
et
al
influenzalikeil
ili
place
signific
burden
healthcar
system
rudan
et
al
unit
state
life
year
lost
cost
billion
everi
influenza
season
molinari
et
al
reduc
risk
hospit
transmiss
recommend
patient
suspect
either
influenza
rsv
infect
presumpt
isol
side
room
cohort
patient
confirmatori
test
avail
guy
st
thoma
nh
foundat
trust
public
health
england
patient
confirm
influenza
present
activ
influenza
season
offer
antivir
treatment
within
hour
symptom
onset
public
health
england
howev
prescrib
antivir
remain
low
hospit
children
elig
receiv
medic
seal
et
al
wilk
et
al
central
laboratori
test
respiratori
sampl
slow
douthwait
et
al
reduc
turnaround
time
may
enabl
earlier
appropri
treatment
improv
cohort
isol
strategi
prevent
transmiss
enzym
immunoassay
base
pointofcar
test
poct
influenza
rsv
avail
sever
year
health
technolog
apprais
found
littl
benefit
use
devic
nearpati
set
nicholson
et
al
moreov
test
lower
sensit
compar
pcrbase
devic
boku
et
al
dimaio
et
al
goldenberg
edgeworth
new
multiplex
pcrbase
poct
fluabrsv
pcr
assay
enigma
diagnost
ltd
salisburi
uk
becam
avail
perform
characterist
commonli
use
laboratori
base
respiratori
pathogen
panel
poct
assay
summar
tabl
appendix
supplementari
data
lope
et
al
luminex
molecular
diagnost
perezruiz
et
al
undertook
realworld
evalu
assess
impact
introduc
fluabrsv
poct
pediatr
ward
compar
current
care
use
laboratori
test
evalu
length
stay
electron
record
drug
prescript
includ
oseltamivir
antibiot
laboratori
test
associ
cost
drug
prescript
laboratori
test
reimburs
charg
evalu
conduct
acut
pediatr
ward
evelina
london
children
hospit
guy
st
thoma
nh
foundat
trust
patient
suspect
ili
typic
symptom
fever
headach
myalgia
cough
coryza
pharyng
bronchiol
typic
present
one
follow
fever
rhiniti
cough
increas
work
breath
wheez
inpati
admiss
data
collect
main
influenza
season
novemb
februari
two
consecut
year
patient
respiratori
viral
panel
rvp
luminex
corp
austin
tx
order
within
hour
admiss
patient
admit
season
rvp
use
period
compar
data
collect
retrospect
season
poct
rvp
use
parallel
period
period
poct
avail
use
hour
day
day
week
patient
admit
mountain
ward
requir
swab
taken
respiratori
viru
diagnost
test
final
sampl
size
period
period
see
appendix
detail
supplementari
data
staff
encourag
act
poct
result
although
formal
protocol
introduc
studi
outcom
present
perspect
nation
health
servic
nh
research
ethic
committe
approv
waiv
classifi
servic
evalu
manufactur
poct
fund
studi
role
analysi
report
find
four
outcom
use
assess
impact
poct
length
stay
drug
util
oseltamivir
antibiot
overal
drug
cost
ancillari
laboratori
test
util
cost
tariff
reimburs
charg
total
inpati
admiss
reimburs
attribut
time
spent
acut
pediatr
ward
patient
level
prescrib
data
avail
electron
patient
record
obtain
entir
hospit
stay
includ
cost
pharmaci
suppli
item
admiss
oseltamivir
antibiot
immunoglobulin
prescrib
identifi
cost
medic
prescrib
year
convert
drug
price
determin
estim
averag
total
drug
cost
per
admiss
drug
administ
ward
stock
captur
electron
patient
data
potenti
relev
antibiot
includ
amoxicillin
benzylpenicillin
cephalexin
cefotaxim
ceftazidim
ceftriaxon
cefuroxim
clarithromycin
clindamycin
coamoxiclav
erythromycin
flucloxacillin
gentamicin
metronidazol
trimethoprim
vancomycin
admiss
number
laboratori
test
obtain
admiss
test
data
exclud
analysi
test
cost
price
hospit
laboratori
provid
use
unpublish
reimburs
charg
repres
payment
made
hospit
payor
complet
patient
admiss
estim
standard
associ
care
cost
staff
hotel
indirectoverhead
standard
diagnost
medic
procedur
reimburs
charg
admiss
nh
code
health
care
resourc
group
hrg
group
activ
base
intern
classif
diseas
version
diagnost
code
specif
procedur
intervent
perform
admiss
nh
digit
given
code
factor
includ
admiss
type
elect
emerg
present
complic
length
stay
special
topup
servic
determin
final
reimburs
charg
hrg
code
reimburs
charg
use
period
analysi
nh
digit
descript
statist
report
elig
admiss
period
includ
age
month
sex
complic
admiss
relev
condit
discharg
respiratori
hrg
code
admiss
high
depend
unit
hdu
total
length
stay
length
stay
acut
pediatr
ward
proport
admiss
oseltamivir
antibiot
immunoglobulin
prescrib
averag
total
drug
cost
per
admiss
averag
number
laboratori
test
per
admiss
per
day
averag
total
test
cost
averag
total
reimburs
charg
averag
acut
pediatr
ward
reimburs
charg
relev
condit
defin
diagnost
code
either
indic
receiv
influenza
vaccin
public
health
england
clinic
associ
respiratori
infect
see
appendix
supplementari
data
includ
control
condit
could
increas
risk
potenti
complic
result
therebi
cost
treat
influenzaor
rsvrelat
infect
certain
hrg
code
distinguish
complic
determin
patient
acuiti
creat
variabl
control
also
creat
variabl
admiss
discharg
respiratori
hrg
code
see
appendix
supplementari
data
proport
posit
result
viru
detect
rvp
period
determin
bivari
test
test
categor
continu
variabl
respect
conduct
variabl
determin
whether
statist
signific
differ
period
examin
effect
use
poct
outcom
oseltamivir
antibacteri
prescrib
use
admiss
period
proxi
estim
odd
ratio
use
logist
regress
regress
model
shown
appendix
supplementari
data
also
conduct
multivari
linear
regress
analys
explor
impact
period
averag
reimburs
charg
cost
drug
laboratori
test
regress
analys
control
potenti
confound
patient
characterist
age
sex
relev
condit
complic
hdu
admiss
effect
cost
laboratori
test
model
poct
use
gatekeep
screen
test
alway
perform
rvp
ie
patient
posit
poct
would
requir
investig
wherea
followup
rvp
would
perform
neg
poct
analyz
remov
cost
rvp
test
perform
period
patient
test
posit
rsv
influenza
ab
poct
see
appendix
supplementari
data
use
assum
cost
poct
test
account
skew
distribut
cost
logarithm
transform
cost
util
outcom
wide
use
strategi
analys
nonnorm
distribut
altman
et
al
duan
garrido
et
al
man
mullahi
see
appendix
supplementari
data
addit
inform
analys
perform
stata
window
statacorp
colleg
station
tx
statist
signific
assum
descript
statist
present
tabl
patient
period
significantli
younger
median
vs
month
p
b
higher
occurr
complic
vs
p
b
prescrib
oseltamivir
antibiot
two
period
significantli
differ
without
control
potenti
confound
also
evid
signific
differ
variabl
signific
differ
period
total
length
stay
median
day
period
p
length
stay
acut
pediatr
ward
median
day
period
p
averag
reimburs
charg
statist
differ
period
slight
increas
number
respiratori
hrg
period
although
signific
vs
p
proport
posit
result
nine
virus
includ
rvp
similar
period
tabl
suggest
overal
burden
infect
similar
year
control
potenti
confound
factor
oseltamivir
prescript
p
ci
admiss
posit
influenza
period
compar
period
margin
statist
signific
observ
signific
differ
noninfluenza
nonrsv
patient
tabl
signific
differ
antibiot
prescrib
period
posit
influenza
neg
influenza
rsv
patient
neg
influenza
rsv
test
found
reduct
averag
reimburs
charg
entir
admiss
stay
acut
pediatr
ward
reduct
p
ci
p
ci
respect
cost
save
effect
remain
look
patient
reduct
p
ci
p
ci
respect
tabl
chang
reimburs
patient
proven
influenza
rsv
infect
small
signific
increas
cost
drug
electron
record
period
admiss
patient
posit
influenza
andor
rsv
increas
p
b
ci
use
simpl
model
techniqu
save
cost
laboratori
test
could
realiz
poct
use
screen
gateway
test
follow
rvp
neg
influenzarsv
result
base
poct
cost
averag
estim
save
would
p
b
ci
admiss
biggest
differ
cost
save
posit
influenzarsv
patient
save
p
b
ci
first
evalu
use
pcrbase
poct
influenza
rsv
pediatr
inpati
ward
set
although
random
control
trial
studi
suggest
increas
accur
oseltamivir
prescrib
patient
influenza
follow
introduct
poct
may
due
improv
complianc
clinic
guidelin
nice
model
data
account
differ
patient
group
period
suggest
reduc
reimburs
charg
patient
without
influenza
rsv
despit
observ
chang
length
stay
also
note
reduc
cost
laboratori
test
patient
poct
implement
assum
poct
result
consist
prior
research
show
poct
increas
appropri
oseltamivir
use
pediatr
hospit
bonner
et
al
may
confirm
diagnosi
achiev
admiss
therebi
allow
clinician
prescrib
oseltamivir
within
hour
onset
symptom
greatest
therapeut
effect
nice
period
patient
influenza
receiv
oseltamivir
could
neg
consequ
patient
care
poct
could
enabl
time
effect
care
patient
observ
signific
reduct
oseltamivir
prescrib
patient
test
neg
influenza
rsv
period
indic
tendenc
toward
decreas
prescrib
realworld
evalu
observ
might
due
clinician
unfamiliar
thu
less
trust
poct
therefor
continu
prescrib
oseltamivir
ongo
sign
symptom
ili
result
antibiot
prescript
influenza
posit
patient
reach
statist
signific
odd
prescrib
antibiot
estim
halv
posit
influenza
period
compar
studi
evalu
impact
rapid
diagnost
influenza
pediatr
emerg
depart
set
detect
signific
reduct
antibiot
prescript
group
clinician
inform
posit
result
flu
rapid
test
bonner
et
al
howev
studi
mani
antibiot
could
administ
directli
ward
suppli
data
use
unavail
us
electron
patient
record
henc
know
true
chang
antibiot
use
across
time
period
small
observ
increas
drug
cost
period
influenza
andor
rsv
would
hope
poct
might
facilit
better
antimicrobi
stewardship
patient
suspect
respiratori
viral
infect
studi
need
assess
averag
number
laboratori
test
order
remain
unchang
period
estim
test
cost
decreas
period
less
expens
followup
test
may
request
follow
poct
result
despit
chang
test
guidelin
chang
practic
observ
previous
bonner
et
al
suggest
poct
could
function
gateway
screen
test
prevent
use
addit
expens
test
benefit
provid
faster
result
could
seen
poct
implement
set
perform
fewer
expens
test
could
costsav
healthcar
provid
treat
patient
respiratori
season
could
reason
expect
result
similar
greater
magnitud
observ
studi
poct
deploy
emerg
depart
test
perform
patient
arriv
ward
period
reimburs
charg
entir
admiss
stay
acut
pediatr
ward
decreas
patient
neg
result
influenza
rsv
control
known
complic
result
residu
confound
effect
modif
minim
observ
chang
length
stay
period
suggest
chang
reimburs
due
differ
length
hospit
admiss
howev
reimburs
charg
determin
rang
variabl
difficult
specif
attribut
reduct
reimburs
poct
although
may
factor
note
differ
epidemiolog
influenza
infect
report
public
health
england
peak
rate
hospit
age
higher
peak
seen
howev
uk
sentinel
hospit
surveil
indic
proport
confirm
influenza
confirm
hospit
case
age
year
lower
respect
excess
allcaus
mortal
age
group
increas
despit
differ
observ
signific
differ
distribut
respiratori
virus
studi
period
tabl
convers
observ
greater
rate
record
complic
vs
p
b
respect
studi
popul
furthermor
rate
nation
uptak
live
attenu
influenza
vaccin
old
lower
respect
compar
respect
overal
vaccin
effect
may
also
differ
two
period
caspard
et
al
known
differ
may
studi
find
exampl
possibl
chang
oseltamivir
prescrib
influenc
increas
incid
influenza
andor
increas
caus
excess
mortal
two
period
howev
nation
data
paramet
measur
studi
popul
possibl
draw
definit
conclus
tabl
odd
ratio
prescript
oseltamivir
antibiot
two
period
period
compar
period
admiss
neg
influenza
rsv
sever
limit
studi
first
potenti
unobserv
factor
might
influenc
result
instanc
evalu
control
unobserv
timevari
factor
also
studi
perform
hospit
attempt
improv
code
practic
may
independ
contribut
result
second
unfamiliar
poct
test
clinician
may
still
reli
rvp
result
make
clinic
decis
believ
result
like
underestim
true
effect
implement
test
could
test
becom
embed
trust
clinician
studi
undertaken
one
center
find
may
generaliz
howev
term
resourc
util
believ
impact
poct
pediatr
inpati
ward
may
similar
observ
studi
given
similar
pattern
influenza
rsv
lastli
unabl
determin
whether
patient
place
cohort
gener
ward
isol
bed
inform
reliabl
record
patient
record
unabl
assess
impact
poct
bed
manag
result
questionnair
conduct
time
studi
suggest
ward
staff
felt
test
improv
bed
manag
result
avail
upon
request
author
recommend
conduct
time
motion
analysi
captur
cost
driver
staff
time
studi
also
explor
packag
antimicrobi
stewardship
intervent
involv
influenzarsv
poct
includ
staff
train
best
prescrib
practic
follow
poct
result
studi
demonstr
poct
may
potenti
improv
appropri
effici
manag
ili
pediatr
patient
strengthen
antimicrobi
stewardship
practic
conflict
interest
sd
report
grant
enigma
diagnost
ltd
conduct
studi
previou
grant
beckton
dickinson
time
studi
eja
aivo
cyc
reg
cm
employ
aquariu
popul
health
receiv
project
fund
cepheid
atla
genet
organ
poct
govern
nihr
fund
unrel
work
sg
report
grant
enigma
diagnost
ltd
conduct
studi
person
fee
becton
dickinson
grant
person
fee
luminex
corp
grant
person
fee
astella
person
fee
abbott
person
fee
merck
person
fee
qiagen
grant
biorad
grant
genmark
diagnost
outsid
submit
work
